|Bid||310.65 x 900|
|Ask||311.99 x 1200|
|Day's range||307.44 - 316.88|
|52-week range||119.01 - 319.19|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||70.16|
|Earnings date||29-Oct-2020 - 02-Nov-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||302.40|
ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.
Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Abiomed announces Q1 FY 2021 revenue of $165 million and 21% operating margin.